90 related articles for article (PubMed ID: 20218623)
1. Emerging targets in osteoporosis disease modification.
Allen JG; Fotsch C; Babij P
J Med Chem; 2010 Jun; 53(11):4332-53. PubMed ID: 20218623
[No Abstract] [Full Text] [Related]
2. Markers of bone turnover: consideration on their clinical application in osteoporosis.
Cantatore FP; Pipitone V
Panminerva Med; 1999 Sep; 41(3):247-51. PubMed ID: 10568124
[TBL] [Abstract][Full Text] [Related]
3. Androgen supplementation in eugonadal men with osteoporosis: effects of six months' treatment on markers of bone formation and resorption.
Anderson FH; Francis RM; Peaston RT; Wastell HJ
J Bone Miner Res; 1997 Mar; 12(3):472-8. PubMed ID: 9076591
[TBL] [Abstract][Full Text] [Related]
4. [Strontium ranelate's (Osseor) dual mode of action: increasing bone mass and decreasing bone resorption].
Kaliterna DM
Reumatizam; 2008; 55(2):73-4. PubMed ID: 19024281
[TBL] [Abstract][Full Text] [Related]
5. Issues in designing and testing a "cure" for osteoporosis.
Cummings S
J Musculoskelet Neuronal Interact; 2004 Dec; 4(4):408. PubMed ID: 15758283
[No Abstract] [Full Text] [Related]
6. [Early, noninvasive diagnostic of osteoporosis in men].
Lepiarz-Rusek W; Kokocińska D
Przegl Lek; 2005; 62(7):641-9. PubMed ID: 16463693
[TBL] [Abstract][Full Text] [Related]
7. Clinical applications of RANK-ligand inhibition.
Romas E
Intern Med J; 2009 Feb; 39(2):110-6. PubMed ID: 19356186
[TBL] [Abstract][Full Text] [Related]
8. Is BMD measurement an adequate surrogate for anti-fracture efficacy?
Gandolini G; Salvioni PM
Aging Clin Exp Res; 2004 Jun; 16 Suppl(3):29-32. PubMed ID: 15506698
[No Abstract] [Full Text] [Related]
9. Alendronate reduces serum TNFalpha and IL-1beta, increases neutrophil counts, and improves bone mineral density and bone metabolism indices in patients with chronic idiopathic neutropenia (CIN)-associated osteopenia/osteoporosis.
Papadaki HA; Tsatsanis C; Christoforidou A; Malliaraki N; Psyllaki M; Pontikoglou C; Miliaki M; Margioris AN; Eliopoulos GD
J Bone Miner Metab; 2004; 22(6):577-87. PubMed ID: 15490268
[TBL] [Abstract][Full Text] [Related]
10. Systemic assessments utilizing saliva: part 2 osteoporosis and use of saliva to measure bone turnover.
Koka S; Forde MD; Khosla S
Int J Prosthodont; 2006; 19(1):53-60. PubMed ID: 16479761
[TBL] [Abstract][Full Text] [Related]
11. Secondary osteoporosis in liver transplant recipients: a longitudinal study in patients with and without cholestatic liver disease.
Bjøro K; Brandsaeter B; Wiencke K; Bjøro T; Godang K; Bollerslev J; Schrumpf E
Scand J Gastroenterol; 2003 Mar; 38(3):320-7. PubMed ID: 12737449
[TBL] [Abstract][Full Text] [Related]
12. Serum leptin is correlated to high turnover in osteoporosis.
Hipmair G; Böhler N; Maschek W; Soriguer F; Rojo-Martínez G; Schimetta W; Pichler R
Neuro Endocrinol Lett; 2010; 31(1):155-60. PubMed ID: 20150868
[TBL] [Abstract][Full Text] [Related]
13. Is systemic treatment of osteoporosis and mandibular resorption possible?
Driessens FC; Verbeeck RM; Van Dijk JW
Acta Stomatol Belg; 1990 Jun; 87(2):107-24. PubMed ID: 2256451
[TBL] [Abstract][Full Text] [Related]
14. Endocrine regulation of bone turnover in men.
Meier C; Liu PY; Handelsman DJ; Seibel MJ
Clin Endocrinol (Oxf); 2005 Dec; 63(6):603-16. PubMed ID: 16343093
[No Abstract] [Full Text] [Related]
15. The mineralization of bone tissue: a forgotten dimension in osteoporosis research.
Boivin G; Meunier PJ
Osteoporos Int; 2003; 14 Suppl 3():S19-24. PubMed ID: 12730799
[TBL] [Abstract][Full Text] [Related]
16. Continuous improvement of bone mineral density two years post zoledronic acid discontinuation in patients with thalassemia-induced osteoporosis: long-term follow-up of a randomized, placebo-controlled trial.
Voskaridou E; Christoulas D; Konstantinidou M; Tsiftsakis E; Alexakos P; Terpos E
Haematologica; 2008 Oct; 93(10):1588-90. PubMed ID: 18698086
[No Abstract] [Full Text] [Related]
17. [Management of bone diseases associated with kidney failure in the elderly].
Choukroun G
Rev Prat; 2005 Dec; 55(20):2245-7. PubMed ID: 16519051
[No Abstract] [Full Text] [Related]
18. The value of biochemical markers of bone turnover in osteoporosis.
Eastell R; Blumsohn A
J Rheumatol; 1997 Jun; 24(6):1215-7. PubMed ID: 9195539
[TBL] [Abstract][Full Text] [Related]
19. [Osteoporosis-profile--a bad examination?].
Sørensen OH; Nielsen SP; Thode J; Eriksen EF
Ugeskr Laeger; 1994 Sep; 156(38):5503-5. PubMed ID: 7941083
[TBL] [Abstract][Full Text] [Related]
20. [Treatment of osteoporosis with antiresorptive drugs].
Vestergaard P; Mosekilde L; Brixen K
Ugeskr Laeger; 2005 Feb; 167(8):883-7. PubMed ID: 15789840
[No Abstract] [Full Text] [Related]
[Next] [New Search]
